Table 2.
Association of Programmed Death-Ligand 1 Expression and Clinicopathologic Characteristics
| Parameters | Total | PD-L1 Expression on ICs | P | ||
|---|---|---|---|---|---|
| IC0 | IC1 | IC2/3 | |||
| Age | 0.654 | ||||
| <65.0 | 109 | 13 (11.9) | 28 (25.7) | 68 (62.4) | |
| ≥65.0 | 110 | 16 (14.5) | 32 (29.1) | 62 (56.4) | |
| Gender | 0.569 | ||||
| Male | 177 | 22 (12.4) | 47 (26.6) | 108 (61.0) | |
| Female | 42 | 7 (16.7) | 13 (30.9) | 22 (52.4) | |
| Tumor stage | 0.640 | ||||
| pT2 | 29 | 5 (17.3) | 9 (31.0) | 15 (51.7) | |
| pT3–4 | 190 | 24 (12.6) | 51 (26.9) | 115 (60.5) | |
| Concomitant CIS | 0.324 | ||||
| Yes | 122 | 18 (14.8) | 37 (30.3) | 67 (54.9) | |
| No | 97 | 11 (11.3) | 23 (23.7) | 63 (65.0) | |
| LVI | 0.154 | ||||
| Yes | 142 | 21 (14.8) | 33 (23.2) | 88 (62.0) | |
| No | 77 | 8 (10.4) | 27 (35.1) | 42 (54.5) | |
| Lymph node positivity | 0.003 | ||||
| Negative | 102 | 22 (21.6) | 26 (25.5) | 54 (52.9) | |
| Positive | 117 | 7 (6.0) | 34 (29.1) | 76 (64.9) | |
| Surgical margin status | 0.462 | ||||
| Negative | 179 | 24 (13.4) | 52 (29.1) | 103 (57.5) | |
| Positive | 40 | 5 (12.5) | 8 (20.0) | 27 (67.5) | |
| Histologic subtype | 0.333 | ||||
| Pure UC | 167 | 19 (11.4) | 46 (27.5) | 102 (61.1) | |
| Mixed UC | 52 | 10 (19.3) | 14 (26.9) | 28 (53.8) | |
| Type of urinary diversion | 0.786 | ||||
| Ileal conduit | 24 | 3 (12.5) | 8 (33.3) | 13 (54.2) | |
| Orthotopic neobladder | 195 | 26 (13.3) | 52 (26.7) | 117 (60.0) | |
Abbreviations: CIS, carcinoma in situ; LVI, lymphovascular invasion; UC, urothelial carcinoma; PD-L1, programmed death-ligand 1; IC, immune cell.